Abstract: The present invention relates to a novel process of production of purified recombinant cholera toxin B (rCTB) which provides protection against diarrhea caused by various bacteria such as Vibrio cholerae and Enterotoxigenic Escherichia coli (ETEC). More particularly, the present invention relates to a process of production of rCTB with significantly higher yield and higher purity. The present invention also relates to a vaccine formulation having synergistic protection against Vibrio cholerae and cross protection against ETEC.

Abstract: The present invention relates to an improved thermostable spray dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses thermostable liquid, powder or granule-based rotavirus vaccine prepared using the spray drying process, such that the said vaccine has improved heat-stability, ease-of-use, ease-of-transportation and affordability features with significantly better chance of being adopted in developing and low income country's vaccination program.

Abstract: The present invention relates to a thermostable freeze dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses multivalent thermostable liquid, powder or cake based rotavirus vaccine formulation prepared using the freeze drying process, such that the said vaccine formulation possess improved heat-stability, easy to use and transport and highly affordable thereby meeting the requirements of developing and low income country's vaccination program. The said freeze dried rotavirus vaccine formulation along with reconstitution buffer is so engineered to be suitable for filling in appropriate packaging containers/ closures so designed such that they reduce the logistics requirement for storage.

Abstract: The present invention relates to a novel process of production of purified recombinant cholera toxin B (rCTB) which provides protection against diarrhea caused by various bacteria such as Vibrio cholerae and Enterotoxigenic Escherichia coli (ETEC). More particularly, the present invention relates to a process of production of rCTB with significantly higher yield and higher purity. The present invention also relates to a vaccine formulation having synergistic protection against Vibrio cholerae and cross protection against ETEC.

Abstract: The present invention relates to an improved thermostable spray dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses thermostable liquid, powder or granule-based rotavirus vaccine prepared using the spray drying process, such that the said vaccine has improved heat-stability, ease-of-use, ease-of-transportation and affordability features with significantly better chance of being adopted in developing and low income country's vaccination program.

Abstract: The present invention relates to a thermostable freeze dried rotavirus vaccine formulation and the process of preparing the same. More specifically the present invention discloses multivalent thermostable liquid, powder or cake based rotavirus vaccine formulation prepared using the freeze drying process, such that the said vaccine formulation possess improved heat-stability, easy to use and transport and highly affordable thereby meeting the requirements of developing and low income country's vaccination program. The said freeze dried rotavirus vaccine formulation along with reconstitution buffer is so engineered to be suitable for filling in appropriate packaging containers/ closures so designed such that they reduce the logistics requirement for storage.

Abstract: The present invention relates to a novel influenza vaccine, a novel plasmid for preparing the same and a novel dosage form comprising the same. The present invention in particular relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of at least four foreign genes from influenza virus, specifically an avian influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome. The invention further relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of not less than two foreign genes from influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome, with the provision that at least one foreign gene is either PB2 or M2e. The invention also provides composition and methods of making the universal influenza vaccine.